Advertisement

Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

Latest from Weill Cornell Medical College Sandra & Edward Meyer Cancer Center


Thymic Cancer Experts Discuss the Latest Data, Need for More Research Funding

October 31, 2022

Drs Giaccone and He discuss the implications of their thymic cancer research, the importance of combining immunotherapy and anti-angiogenesis agents to treat solid tumors, and the challenges of investigating rare cancers.

Women in Oncology: Prioritization and Passionate Legacies

August 30, 2022

Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.

Women in Oncology: Bringing Advances From the Lab Into the Clinic

August 19, 2022

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss what motivated them to continue working toward improvements in the leukemia field, even when outcomes were dismal and treatment options were scarce.

Women in Oncology: How Early Treatments Paved the Way for Future Advances

August 18, 2022

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss the challenges that accompanied the lack of progress in leukemia treatment when they began their fellowships and express their excitement about encouraging developments that have since emerged in the arena.

Maintenance Rituximab Prolongs Time to Next Treatment, OS in MCL

August 17, 2022

Maintenance rituximab following first-line bendamustine plus rituximab or a combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone prolonged first-line treatment benefits and improved survival outcomes vs either induction regimen alone.

Two Fellows Use Online Resources to Boost Genetic Testing

April 16, 2022

Widespread germline testing in the United States could prevent cancer in hundreds of thousands of people. However, despite known benefits, uptake for genetic testing has been slow: only 1 in 5 individuals use recommended genetic services even when there is a significant family history of colorectal, breast, or ovarian cancer.

Tagawa Breaks Down FGFR Testing and the Use of Erdafitinib in Bladder Cancer

November 08, 2021

Dr. Tagawa discusses the incidence and identification of FGFR alterations in bladder cancer, the approval and use of erdafitinib in the second-line setting for patients with advanced bladder cancer, and research directions with the FGFR inhibitor in the field.

It’s Not a Small World for Small Cell Lung Cancer Treatment

October 27, 2021

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, discuss the latest findings in small cell lung cancer based on studies that were presented during the 2021 ESMO Congress, 2021 World Conference on Lung Cancer, and 2021 ASCO Annual Meeting.

Advertisement
Advertisement